Lyme Disease Diagnostic Devices Market Size, Share By Product Type (Serological Test, Urine Antigen Tests, Lymphocytic Transformation Test, Immunofluorescent Staining, and Nucleic acid Test), By End User (Hospitals, Public/Private Laboratories, and Physician’s Office) - Global Industry Analysis, Trends, Growth, Segment Forecasts, Regional Outlook 2023 - 2032

The global lyme disease diagnostic devices market size surpassed USD 2.52 billion in 2022 and is predicted to hit around USD 4.01 billion by 2032, with an impressive CAGR of 5.3% during the forecast period 2023 to 2032.

Access our Premium Real Time Data Intelligence Tool, Visit: Precedence Statistics

Key Takeaways

• North America led the global market with the largest market share in 2022.
• By Product, the serological test segment has held the largest revenue share in 2022.
• By Product, the lymphocytic transformation tests segment is anticipated to expand at a significant CAGR during the projected period.
• By End User, the hospitals segment has held the largest revenue share in 2022.

Key market Insights:

Upsurge in incidence of Lyme disease, growing policy attention on improving health care services, and the advent of new diagnostic tests for Lyme disease pushes the market. Nonetheless, lack of knowledge of the disease and ineffectiveness in Lyme disease research reduces the market. Additionally, growth in key players’ interests in Lyme disease diagnosis R&D is predicted to provide lucrative business growth opportunities. Moreover, increasing number of cases of tick-borne infectious diseases is boosting Lyme disease diagnostics market. Vector-borne diseases are illnesses caused by pathogens and parasites in human inhabitants. Each year greater than 1 billion individuals are infected and higher than 1 million people die from vector-borne illnesses. They can be infected by bacteria, parasites or viruses. More than 16% of the ailment and disability endured globally is because of vector-borne illnesses, with more than 50% of world’s population presently assessed to be at risk of these ailments.

Crucial factors accountable for market growth are:

• Growing prevalence of Lyme disease
• Increasing number of cases of tick-borne infectious diseases
• Growing investment in research and development
• Technological advancement
  

Lyme Disease Diagnostic Devices Market Scope 

Product Insights

Serological Test Segment Reported Foremost Market Stake in 2022

Serological test segment recorded the prime market share in the global Lyme disease diagnostic devices market by type in 2022. Increasing use in the early diagnosis of Lyme disease diagnostics is the major reason for high market share of serological test. Other factors such as increasing investment in research and development is expected to increase the usage of serological tests over the estimate period.

The lymphocytic transformation tests are projected grow at the highest CAGR during the forecast period mainly due to new product launches in the near future.

End User Insights

Hospitals are Projected to Dominate the End User Segment of Lyme Disease Diagnostic Devices Market Revenue

The Lyme disease diagnosis is based on infection signs and symptoms, history of exposures to infected black-legged ticks, and laboratory tests. Serological tests can take several weeks to become conclusive after infection, indicating the need for new diagnostic tests that can identify the earliest signs of infection. Hospitals are well-equipped to handle patient flow and employ latest diagnostic and treatment techniques. These factors are primarily responsible for the greater market share of hospitals in the end-user segment of the Lyme Disease Diagnostic Devices Market.

Public/private laboratories segment will expand at a significant CAGR during the forecast time-frame.

Regional Insights

North America is Estimated to be the Largest Market for Lyme Disease Diagnostic Devices

The research report covers key trends and prospects of Lyme disease diagnostic devices products across different geographical regions including North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa. Geographically, Lyme disease diagnostic devices market is conquered by North America owing to high incidence of Lyme disease and existence of state-of-the-art healthcare infrastructure. On the other hand, Asia-Pacific is anticipated to witness the rapid growth rate, on account of increasing research and development investment by major market players and increasing awareness regarding tick-borne infectious disorders.

Lyme Disease Diagnostic Devices Market Players

The companies focusing on research and development are expected to lead the global Lyme disease diagnostic devices market. Leading competitors contending in global Lyme disease diagnostic devices market are as follows:

• Bio-Rad Laboratories, Inc.
• Thermo Fisher Scientific, Inc.
• Boulder Diagnostics
• T2 Biosystems, Inc.
• Abbott
• Oxford Immunotec Global PLC
• Quidel Corporation
• Affymetrix Inc.
• Hoffmann-La Roche Ltd
• Graphene Frontiers

In order to better recognize the current status of Lyme disease diagnostic devices, and policies adopted by the foremost countries, Precedence Research predicted the future evolution of the Lyme disease diagnostic devices market. This research study bids qualitative and quantitative insights on Lyme disease diagnostic devices market and assessment of market size and growth trend for potential market segments.

Major Market Segments Covered:

By Product Type

• Serological Test
• Urine Antigen Tests
• Lymphocytic Transformation Test
• Immunofluorescent Staining
• Nucleic acid Test

By End User

• Hospitals
• Public/Private Laboratories
• Physician’s Office

By Geography

• North America
• U.S.
• Canada
• Europe
• Germany
• France
• United Kingdom
• Rest of Europe
• Asia Pacific
• China
• Japan
• India
• Southeast Asia
• Rest of Asia Pacific
• Latin America
• Brazil
• Rest of Latin America
• Middle East & Africa (MEA)
• GCC
• North Africa
• South Africa
• Rest of Middle East & Africa